LIPID:B2
*Based on experimental studies carried out by Pierre Fabre Laboratories
XeraCalm
XERACALM AD - Replenishing Cream
Permanent
XeraCalm
Permanent Soothes - Soothes itching - Spaces flare-ups of dryness* - Strengthens the skin barrier
A TRIPLE-ACTION CARE that helps improve, from the very first month of use, the quality of life of very dry to atopic skin prone to itching.
MOISTURIZES FOR 48-HOUR*
Usable by From birth - Pregnant women - People undergoing anti-cancer treatment or post-treatment
Skin type Dry skin prone to atopic eczema - Dry skin - Sensitive skin
Need Nourishment - Anti-scratch - Apaisement
Made in France
EMERGENCY: very dry to atopic skin prone to itching?
XERACALM A.D Cream has been reinvented to deliver enhanced efficacy.
This high-tolerance care helps restore the skin barrier and rebalance the microbiome thanks to a new combination of advanced active ingredients:
• I-MODULIA⁺, an optimised version of our patented anti-itching active, targets imbalances at the heart of the microbiome that are responsible for discomfort and episodes of dryness.
• LIPID:B2 Complex stimulates the natural synthesis of ceramides, essential to skin protection.
Result: the skin is soothed immediately… and lastingly!
Fragrance-free, non-comedogenic and packaged under sterile conditions, XERACALM A.D Cream ensures maximum efficacy, safety and tolerance, even on the most sensitive skin or skin weakened by specific oncological or dermatological treatments.
A lipid-replenishing cream that restores the skin's barrier function and skin comfort.
• ANTI-ITCHING : effectiveness recognised by dermatologists from the European Dermatology Forum in the management of atopic eczema (category "Emollient PLUS**).
• LIPID-REPLENISHING : relieves very dry skin prone to atopic eczema and itching.
• SOOTHING thanks to the Avène Thermal Spring Water.
*Instrumental test, twice daily application for 7 days on 20 subjects.
*Clinical scoring, twice daily application for 3 months, 55 subjects, reduces the risk of recurrence of severe dryness flare-ups.
**"Topical formulation with additional non-medicinal excipients and active ingredients". Recognised by the European Dermatology Forum – Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis), 2018.